UroGen Pharma Ltd. Increase (Decrease) in Other Noncurrent Assets
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Other Noncurrent Assets of $3.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-05
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $1.27M, a 194.88% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $2.33M.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$1.60M, a 829.68% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $5.96M.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for fiscal 2025 was $4.57M.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for fiscal 2024 was -$1.45M.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for fiscal 2023 was -$702.00K, a 155.32% decline from fiscal 2022.
- UroGen Pharma Ltd. increase (decrease) in other noncurrent assets for fiscal 2022 was $1.27M, a 24.41% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.60M 10-Q · filed 2026-08-05 | $2.00M derived: sum of 3 quarters · filed 2026-08-05 | $7.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.33M 10-Q · filed 2026-05-06 | $734.00K derived: sum of 2 quarters · filed 2026-05-06 | $6.69M derived: sum of 3 quarters · filed 2026-05-06 | $7.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.36M derived: sum of 2 quarters · filed 2026-03-02 | $4.79M derived: sum of 3 quarters · filed 2026-08-05 | $4.57M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.39M derived: sum of 2 quarters · filed 2026-08-05 | $6.17M 10-Q · filed 2025-11-06 | $6.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $430.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $212.00K 10-Q · filed 2026-08-05 | $431.00K derived: sum of 3 quarters · filed 2026-08-05 | $128.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$218.00K 10-Q · filed 2026-05-06 | $1.00K derived: sum of 2 quarters · filed 2026-05-06 | -$302.00K derived: sum of 3 quarters · filed 2026-05-06 | -$727.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$84.00K derived: sum of 2 quarters · filed 2026-03-02 | -$509.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.45M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$728.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.67M 10-Q · filed 2025-11-06 | -$1.68M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.36M 10-Q · filed 2025-08-07 | -$1.38M derived: sum of 3 quarters · filed 2025-08-07 | -$2.14M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$940.00K 10-Q · filed 2025-05-12 | -$952.00K derived: sum of 2 quarters · filed 2025-05-12 | -$1.72M derived: sum of 3 quarters · filed 2025-05-12 | -$2.06M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$779.00K derived: sum of 2 quarters · filed 2025-03-10 | -$1.12M derived: sum of 3 quarters · filed 2025-03-10 | -$702.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$767.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.11M derived: sum of 2 quarters · filed 2024-11-06 | -$690.00K 10-Q · filed 2024-11-06 | -$421.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $77.00K 10-Q · filed 2024-08-13 | $346.00K derived: sum of 3 quarters · filed 2024-08-13 | $902.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $421.00K 10-Q · filed 2024-05-13 | $690.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.25M derived: sum of 3 quarters · filed 2024-05-13 | $1.52M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $825.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.10M derived: sum of 3 quarters · filed 2024-03-14 | $1.27M 10-K · filed 2024-03-14 |
| 2022-09-30 | $556.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $831.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.00M 10-Q · filed 2023-11-14 | $447.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $444.00K 10-Q · filed 2023-08-10 | -$109.00K derived: sum of 3 quarters · filed 2023-08-10 | $438.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $169.00K 10-Q · filed 2023-05-11 | -$384.00K derived: sum of 2 quarters · filed 2023-05-11 | $163.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$553.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$6.00K derived: sum of 2 quarters · filed 2023-03-24 | $1.02M derived: sum of 3 quarters · filed 2023-03-24 | $1.02M 10-K · filed 2023-03-24 |
| 2021-09-30 | $547.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.57M derived: sum of 2 quarters · filed 2022-11-10 | $1.57M 10-Q · filed 2022-11-10 | $1.57M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.03M 10-Q · filed 2022-08-11 | $1.03M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |